Results 81 to 90 of about 4,520 (170)

The problem of SARS-CoV-2 virus resistance to direct-acting antivirals

open access: yesБиопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent ...
E. L. Gasich   +6 more
doaj   +1 more source

Early Versus Delayed Usage of Paxlovid in Severe Omicron‐Infected Patients With Hypoxemia: A Prospective Multiple‐Center Cohort Study

open access: yesHealth Science Reports
Background and Aims Early stage administration of Paxlovid has been shown to improve the prognosis of mild to moderate COVID‐19 patients with high risk. However, few evidence was validated in severe COVID‐19 patients with hypoxemia.
Yu‐Ji Wang   +8 more
doaj   +1 more source

Paxlovid Awareness, Reporting Bias. [PDF]

open access: yesHealth affairs (Project Hope)
Widera, Eric, Lee, Todd C, Prasad, Vinay
openaire   +4 more sources

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid

open access: yesKidney International Reports, 2022
Philipponnet, Carole   +4 more
openaire   +2 more sources

Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. [PDF]

open access: yesPharmaceuticals (Basel)
Zhu X   +8 more
europepmc   +1 more source

Cardiovascular Outcomes in COVID-19 Patients Treated with Paxlovid: A Multicenter Retrospective Study. [PDF]

open access: yesActa Cardiol Sin
Chen WL   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy